Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION Regulatory-affairs lead is responsible for to drop a secondary in a safety team sitting on a new disproportionate signal, using CMC comparability package for a site change as the only working extract. A literature paper the 505(b)(2) package leans on getting retracted is what reset the timeline for this Pharma & Life Sciences CMC and Development Pathways file.

DECISION Regulatory-affairs lead in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted.

HYPOTHESES TO TEST 1. CMC comparability package for a site change reads as Proceed under protocol once a literature paper the 505(b)(2) package leans on getting retracted is lined up to the same Pharma & Life Sciences population. 2. CMC comparability package for a site change is closer to Pause the pathway after a literature paper the 505(b)(2) package leans on getting retracted; Proceed under protocol would over-claim this CMC and Development Pathways extract. 3. Escalate safety review is still live in CMC comparability package for a site change for regulatory-affairs lead in a safety team sitting on a new disproportionate signal. 4. CMC comparability package for a site change is missing the fact regulatory-affairs lead needs after a literature paper the 505(b)(2) package leans on getting retracted; stop this Pharma & Life Sciences close.

ANALYSIS REQUIRED 1. Check whether CMC comparability package for a site change supports the labeled claim regulatory-affairs lead would keep. 2. Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal. 3. Trace CMC, labeling, or pharmacovigilance facts in CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted. 4. For this Pharma & Life Sciences CMC and Development Pathways file, read CMC comparability package for a site change against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move to drop a secondary for regulatory-affairs lead.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / CMC and Development Pathways packet (CMC comparability package for a site change after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option CMC comparability package for a site change can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for regulatory-affairs lead in a safety team sitting on a new disproportionate signal.